90K/LGALS3BP Expression is Upregulated in COVID-19 but Does Not Restrict SARS-CoV-2 Infection

Laure Bosquillon de Jarcy,Bengisu Akbil,Johanna Leyens,Dylan Postmus,Greta Harnisch,Jenny Jansen,Marie Schmidt,Annette Aigner,Fabian Pott,Robert L Chua,Lilian Krist,Roberta Gentile,Barbara Muehlemann,Terence C Jones,Daniela Niemeyer,Julia Fricke,Thomas Keil,Tobias Pischon,Juergen Janke,Christian Conrad,Stefano Iacobelli,Chistian Drosten,Victor M Corman,Markus Ralser,Roland Eils,Florian Kurth,Leif Erik Sander,Christine Goffinet
DOI: https://doi.org/10.1101/2022.07.18.22277255
2022-07-21
MedRxiv
Abstract:Glycoprotein 90K, encoded by the interferon-stimulated gene LGALS3BP, displays broad antiviral activity. It reduces HIV-1 infectivity by interfering with Env maturation and virion incorporation, and increases survival of Influenza A virus-infected mice via antiviral innate immune signaling. Here, we analyzed the expression of 90K/LGALS3BP in 44 hospitalized COVID-19 patients. 90K protein serum levels were significantly elevated in COVID-19 patients compared to uninfected sex- and age-matched controls. Furthermore, PBMC-associated concentrations of 90K protein were overall reduced by SARS-CoV-2 infection in vivo, suggesting enhanced secretion into the extracellular space. Mining of published PBMC scRNA-seq datasets uncovered monocyte-specific induction of LGALS3BP mRNA expression in COVID-19 patients. In functional assays, neither 90K overexpression in susceptible cell lines nor exogenous addition of purified 90K consistently inhibited SARS-CoV-2 infection. Our data suggests that 90K/LGALS3BP contributes to the global type I IFN response during SARS-CoV-2 infection in vivo without displaying detectable antiviral properties.
What problem does this paper attempt to address?